Navigation Links
Par Pharmaceutical Reports Third-Quarter 2007 Results
Date:12/20/2007

ion, respectively. Partially offsetting the increases were lower sales of certain existing products due to competitive pressures, including fluticasone, various amoxicillin products, quinapril, megestrol oral suspension, and doxycycline. Revenues of branded products for the third quarter of 2007 of $24.6 million, an increase of 72.5 percent over the prior year period, were driven by increased sales of Megace(R) ES (megestrol acetate) oral suspension, and fees related to the co-promotion of AndroGel(R).

Par's third-quarter gross margin was 31.2 percent of sales, compared to 31.6 percent in 2006. The Company's gross margin reflects the impact of increased metoprolol succinate ER sales, which have significantly lower gross margin percentages than many of the other products sold by the Company. This impact was offset by increased sales of higher margin products such as propranolol ER and Megace ES, lower inventory write-offs and reduced sales on other lower margin products, including fluticasone.

Research and development (R&D) expenses increased 161.0 percent for the third quarter 2007 compared with the third quarter 2006. The increase was due primarily to costs associated with the in-license of two Phase III products in support of the Company's branded division, Strativa. In July, the Company paid $15 million to BioAlliance Pharma for the US commercialization rights to Loramyc. In August, the Company acquired the North American commercial rights from Hana Biosciences, Inc. ("HANA") for Zensana(TM), at which time the Company made a $5.0 million equity investment in Hana at a contractually agreed premium. Of this amount, $1.2 million representing the premium paid was charged to R&D expense in the quarter. In support of the Company's generic business, Par made a $5.0 million equity investment in IntelliPharmaCeutics Ltd. (IPC), a privately held corporation, to develop and market four controlled release generic drug products. Of this amount, approximately $2.
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Activz Whole-Food Nutrition is ... line offering natural silver healing support† in liquid supplements, ... silver has been used to support natural healing, and ... the most advanced version available. This latest formula, backed ... that supports the existing healing mechanisms in the human ...
(Date:10/31/2014)... News) -- Obesity increases the risk of certain types ... two new U.S. studies show. One study of ... obese increased the risk for estrogen receptor-negative and progesterone ... this for a long time for white women, but ... study author Esther John, a senior research scientist at ...
(Date:10/31/2014)... a lab device to give cancer researchers an unprecedented ... cells spread through the body, causing more than 90 ... how tumor cells travel, the device could uncover new ... from the university,s Whiting School of Engineering and its ... their new system recently in the journal Cancer ...
(Date:10/31/2014)... 2014 Urban Hydroponics, Inc. (OTCQB:URHY), a ... it has signed a Binding Letter of Intent (LOI) ... cultivation sector - Urban Cultivator Inc. (“Urban Cultivator”), BC ... Metal Inc. (“W3 Metal” and together with Urban Cultivator ... to the LOI and an earlier non-binding term sheet, ...
(Date:10/31/2014)... NY (PRWEB) October 31, 2014 In an ... York patients, Dr. Majid Jamali announced he will soon offer ... practice by the end of November. , To build ... Maxillofacial Surgery of New York has become known for, Dr. ... boasts degrees from such top learning institutions as UCLA, Stanford ...
Breaking Medicine News(10 mins):Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 2Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 3Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 4Health News:Study Confirms Obesity-Breast Cancer Link for Blacks, Hispanics 2Health News:Viewing cancer on the move: New device yields close-up look at metastasis 2Health News:Viewing cancer on the move: New device yields close-up look at metastasis 3Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 2Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 3Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 4Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 5Health News:Oral & Maxillofacial Surgery of New York Adds Orthodontic Patient Services 2Health News:Oral & Maxillofacial Surgery of New York Adds Orthodontic Patient Services 3
... analysis finds that a considerable number of clinical cancer ... to pharmaceutical companies. Published in the June 15, 2009 ... the American Cancer Society, the study indicates that conflicts ... results that are favorable to companies. , Ties between ...
... SatisfactionSOUTH BEND, Ind., May 11 In honor of ... to recognize all of its hospital partners for their ... provide."The doctors, nurses, and staff at our partner hospitals ... to be commended," said Rick Siegrist, Press Ganey,s president ...
... of today,s Susan G. Komen Pittsburgh Race for the Cure(R) ... Male: Pat McGuire, Greensburg, Pa., 15:35 , Female: ... , Male: Steven Strelick, 16:05 , Female: ... , Male: Charlie Ban, Pittsburgh, Pa., 16:13 , ...
... to Act as President and COO of iCRco , ... (PRWEB) May ... appointment of Mr. Mark Valentine as the new President and COO. After ... Mr. Valentine assumes the duties of President while keeping the responsibilities of ...
... a $200,000 boost to the 16th Annual EIF Revlon ... out today in Los Angeles. On behalf of Pacific ... sonic skin care, Dr. Robb Akridge , Co-Founder ... to support promising breast cancer research. Entertainment Industry ...
... scientists say , , SATURDAY, May 9 (HealthDay News) ... and viruses, said the U.S. scientists who created the ... used in homes, businesses and health-care settings, shows special ... found in hospitals and cause about 88,000 deaths each ...
Cached Medicine News:Health News:Review finds conflicts of interest in many cancer studies 2Health News:Press Ganey Supports National Hospital Week 2Health News:Press Ganey Supports National Hospital Week 3Health News:17th Annual Komen Pittsburgh Race for the Cure(R) 5K Winners Announced 2Health News:iCRco Names Mark Valentine President and COO 2Health News:Clarisonic Pounds the Pavement 'Pink' Offering Generous Donation at 2009 Entertainment Industry Foundation Revlon Run/Walk for Women 2Health News:Clarisonic Pounds the Pavement 'Pink' Offering Generous Donation at 2009 Entertainment Industry Foundation Revlon Run/Walk for Women 3Health News:Clarisonic Pounds the Pavement 'Pink' Offering Generous Donation at 2009 Entertainment Industry Foundation Revlon Run/Walk for Women 4
(Date:10/31/2014)... 2014  Australian biopharmaceutical company Specialised Therapeutics Australia (STA) ... paclitaxel) in combination with gemcitabine, will be reimbursed via ... pancreatic cancer from 1 November. In ... 5 th most common cause of cancer mortality. ... with the lowest 5-year survival of all common cancers ...
(Date:10/31/2014)... October 31, 2014 Today, Analysts ... CELG ), Bristol-Myers Squibb Co. (NYSE: ... UNH ), Sanofi SA (NYSE: SNY ) ... these notes ahead of publication. To reserve complementary membership, ... ,-- ,Celgene Corporation Research Reports ,On October 23, 2014, ...
(Date:10/31/2014)... 3, 2014 British Journal ... BPH to discuss "male orgasmic dysfunction" with their doctor ... treat prostate symptoms while preserving sexual function   ... publication of a paper in the British Journal of ... prostate to discuss with their doctors the likely impact ...
Breaking Medicine Technology:Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 2Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 3Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 4Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 5Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 6Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 7Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 8Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 2Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 3Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 4Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 5Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 6Sexual Dysfunction No Longer Inevitable When Treating Enlarged Prostate 2
... 31, 2012  Hair Fairies wants clients to "leap" ahead in ... Angeles, San Francisco, Chicago and New York City salons.  With ... full-service clinical salons devoted to natural head lice treatment ... clients who must repeat treatments within six months, to clients ...
... 2012 Neurodevice firm Checkpoint Surgical ... investment round led by the NDI ... secured non-dilutive funding of over $1.3 ... Ohio loan and a $245,000 federal ...
Cached Medicine Technology:Head Lice Can Save You Cash 2Neurodevice Firm Checkpoint Surgical Raises $3M 2
... The Self-Cath family of ... patients a variety of ... Each catheter is ... grade PVC and has ...
... Self-Cath family of 100% ... a variety of options ... Each catheter is made ... PVC and has smooth ...
Used for intermittent self-catheterization of the urethra. The flared proximal end allows the attachment of a syringe for bladder irrigation. Supplied sterile in peel-open packages. Reusable. Intende...
... An indirect immunofluorescence antibody test ... anti-neutrophil cytoplasmic antibodies (ANCA) in human ... sera of patients with necrotizing vasculitides ... to the clinical and other laboratory ...
Medicine Products: